Transcatheter Aortic Valve Replacement for the Treatment of Pure Native Aortic Valve Regurgitation: A Systematic Review.

Franzone, Anna; Piccolo, Raffaele; Siontis, Georgios; Lanz, Jonas; Stortecky, Stefan; Praz, Fabien; Roost, Eva; Vollenbroich, René; Windecker, Stephan; Pilgrim, Thomas (2016). Transcatheter Aortic Valve Replacement for the Treatment of Pure Native Aortic Valve Regurgitation: A Systematic Review. JACC. Cardiovascular Interventions, 9(22), pp. 2308-2317. Elsevier 10.1016/j.jcin.2016.08.049

[img] Text
1-s2.0-S1936879816315485-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

OBJECTIVES This study sought to summarize available evidence on transcatheter aortic valve replacement (TAVR) for the treatment of native pure aortic regurgitation (AR). BACKGROUND Surgical aortic valve replacement (SAVR) is the gold standard for the treatment of AR. However, case series of high-risk patients undergoing TAVR for native pure AR were reported. METHODS We systematically searched Medline, Embase, and Scopus for reports of at least 5 patients with native pure AR undergoing TAVR. Patients' and procedural characteristics were summarized. The primary outcome of interest was all-cause mortality. Pooled estimates were calculated using a random-effects meta-analysis. The study protocol was registered in PROSPERO (CRD42016038422). RESULTS Thirteen reports including 237 patients were included in the analysis. Self-expandable prostheses were used in 79% of patients, whereas 21% of the patients were treated with a balloon-expandable valve. Device success ranged between 74% and 100%. Seventeen patients (7%) required the implantation of a second valve. Conversion to SAVR was reported in 6 (2.5%) cases. The rate of all-cause mortality at 30 days amounted to 7% (95% confidence interval [CI]: 3% to 13%; I(2) = 37%). Cerebrovascular events were rare (0%, 95% CI: 0% to 1%; I(2) = 0); major bleeding and vascular complications occurred in 2% (95% CI: 0% to 7%; I(2) = 41%), and 3% (95% CI: 1% to 7%; I(2) = 0%), respectively. Permanent pacemaker implantation was required in 11% of patients (95% CI: 5% to 19%; I(2) = 50%). The rate of moderate or severe post-procedural AR amounted to 9% (95% CI: 0% to 28%; I(2) = 90%). CONCLUSIONS Among selected patients with native pure AR deemed at high risk for SAVR, TAVR is technically feasible and associated with an acceptable risk of early mortality.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiovascular Surgery

UniBE Contributor:

Franzone, Anna; Piccolo, Raffaele; Siontis, Georgios; Lanz, Jonas; Stortecky, Stefan; Praz, Fabien; Roost, Eva; Vollenbroich, René; Windecker, Stephan and Pilgrim, Thomas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1876-7605

Publisher:

Elsevier

Language:

English

Submitter:

Daniela Huber

Date Deposited:

15 Mar 2017 09:12

Last Modified:

15 Mar 2017 09:12

Publisher DOI:

10.1016/j.jcin.2016.08.049

PubMed ID:

28026742

Uncontrolled Keywords:

meta-analysis; pure native aortic regurgitation; systematic review; transcatheter aortic valve replacement

BORIS DOI:

10.7892/boris.92634

URI:

https://boris.unibe.ch/id/eprint/92634

Actions (login required)

Edit item Edit item
Provide Feedback